Ovarian Cancer
Platinum-treated ovarian cancer patients managed with epoetin alfa
Published in Blood Weekly, June 15th, 2006
"This multicentre, open-label, controlled clinical trial assessed the effects of epoetin alfa treatment on haematologic and quality of life (QOL) parameters in 182 anaemic (Hb{{<=}}12 g/dl) ovarian cancer patients receiving platinum chemotherapy. Patients were randomised 2:1 to receive epoetin alfa 10000-20000 IU three times weekly plus best standard treatment (BST) or BST only," investigators in England reported.
"Main study end points were changes from baseline in haemoglobin (Hb) level, transfusion requirements, and QOL. For the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2006-06-15)
More Articles from Blood Weekly
- Bone Regeneration
PBMSCs may be a new source of circulating osteogenic stem cells for bone regeneration - Cord Blood
Study supports BioLife's approach to preserving umbilical cord blood-derived stem cells - Fanconi Anemia
Fludarabine without irradiation is effective in Fanconi anemia patients undergoing HSCT - Hematopoiesis
Lack of alpha 4 integrin expression in stem cells restricts competitive function and self-renewal - Stem Cell Transplantation
HSCT-related graft failure in thalassemia reduced by unrelated donor selection - Adverse Drug Reaction
Adverse effects of PI-containing regimens may put HIV-infected children at risk for CVD - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
